COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,694 Articles (22,913 medRxiv, 8,781 bioRxiv)

Most recent first Previous |  Page 1220: Articles 12191-12200  | Next

The effect of circulating zinc, selenium, copper and vitamin K1 on COVID-19 outcomes: a Mendelian randomization study
Sobczyk, M. K., Gaunt, T. R.
10.1101/2021.10.18.21265128 — Posted: 2021-10-19
Rapid and Effective Inactivation of SARS-CoV-2 by a Cationic Conjugated Oligomer with Visible Light: Studies of Antiviral Activity in Solutions and on Supports
Kaya, K., Khalil, M. I., Fetrow, B., Fritz, H., Jagadesan, P., Bondu, V., Ista, L., Chi, E. Y., Whitten, D., Schanze, K. S.
10.1101/2021.10.18.464882 — Posted: 2021-10-19
Elevated antibody titers in Abdala vaccinees evaluated by Elecsys(R) anti-SARS-CoV-2 S highly correlate with UMELISA SARS-CoV-2 ANTI RBD, ACE-2 binding inhibition and viral neutralization assays.
Lemos-Perez, G., Chavez-Valdes, S., Gonzalez-Formental, H., Freyre-Corrales, G., Vazquez-Arteaga, A., Alvarez-Acevedo, B., Avila-Diaz, L., Martinez-Rosales, R. U., Chacon-Quintero, Y., Coizeau-Rodriguez, E., Palenzuela-Diaz, A., Noa-Romero, E., Guillen, G.
10.1101/2021.10.18.21265169 — Posted: 2021-10-19
Impact of SARS-CoV-2 infection on longitudinal vaccine immune responses
Havervall, S., Marking, U., Greilert-Norin, N., Gordon, M., Ng, H., Christ, W., Blom, K., Phillipson, M., Nilsson, P., Hober, S., Klingstrom, J., Mangsbo, S., Aberg, M., Thalin, C.
10.1101/2021.10.16.21264948 — Posted: 2021-10-19
Conflicts of interest and physicians' attitudes towards hydroxychloroquine as a treatment against COVID-19: A replication and extension of Roussel & Raoult (2020)
Freget, L., Mulot, M., Rochoy, M., RUGGERI, V., SCHOPFER, C., Cova, F.
10.1101/2021.10.18.21265135 — Posted: 2021-10-19
Shared Genomic Architectures of Covid-19 and Antisocial Behavior: Implications During Pandemics
Adams, C. D., Tielbeek, J., Boutwell, B.
10.1101/2021.10.18.21265145 — Posted: 2021-10-19
δ1 variant of SARS-COV-2 acquires spike V1176F and yields a highly mutated subvariant in Europe
Yang, X.-J.
10.1101/2021.10.16.463825 — Posted: 2021-10-19
SARS-COV-2 C.1.2 variant is highly mutated but may possess reduced affinity for ACE2 receptor
Yang, X.-J.
10.1101/2021.10.16.464644 — Posted: 2021-10-19
SARS-COV-2 γ variant acquires spike P681H or P681R for improved viral fitness
Yang, X.-J.
10.1101/2021.10.16.464641 — Posted: 2021-10-19
Preclinical Efficacy of IMM-BCP-01, a Highly Active Patient-Derived Anti-SARS-CoV-2 Antibody Cocktail
Nikitin, P. A., DiMuzio, J. M., Dowling, J. P., Patel, N. B., Bingaman-Steele, J. L., Nicolescu, C., Heimbach, B. C., Henriquez, N., Polley, A., Howanski, R. J., Nath, M., Shukla, H., Finn, J. P., Liang, L.-f., Smith, T., Storm, N., McKay, L. G. A., Johnson, R. I., Malsick, L. E., Honko, A. N., Griffiths, A., Sarma, P., Geising, D. H., Morin, M. J., Robinson, M. K.
10.1101/2021.10.18.464900 — Posted: 2021-10-19

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).